Antisense oligonucleotide is a promising intervention for liver diseases

Area of Science:

• Hepatology
• Molecular Biology
• Drug Development

Background:

• Liver disease is a major global health concern, progressing through stages from steatosis to cancer.
• Current treatments for liver disease are limited, necessitating novel therapeutic approaches.
• Rising living standards and unhealthy lifestyles contribute to increased liver disease burden.

Purpose of the Study:

• To review the design, modification, delivery, and mechanisms of antisense oligonucleotides (ASO).
• To summarize the application of ASO in treating various liver diseases, including NAFLD, hepatitis, fibrosis, and cancer.
• To discuss the challenges and future perspectives for ASO clinical translation in liver disease therapy.

Main Methods:

• Literature review focusing on antisense oligonucleotide technology.
• Analysis of ASO mechanisms, delivery systems, and modifications.
• Synthesis of current research on ASO efficacy in preclinical and clinical liver disease models.

Main Results:

• ASO demonstrates high efficiency, specificity, low toxicity, and requires low dosage for liver disease intervention.
• ASO has shown potential in treating non-alcoholic fatty liver disease (NAFLD), hepatitis, liver fibrosis, and liver cancer.
• The review details the fundamental aspects of ASO technology relevant to liver disease.

Conclusions:

• Antisense oligonucleotides represent a promising therapeutic strategy for diverse liver diseases.
• Further research and development are needed to overcome challenges in ASO clinical application.
• ASO technology offers a potential breakthrough in managing liver homeostasis and disease progression.